Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Senior Technician - in vivo biology

  • Sutton
  • Research Services
  • Permanent

About you The ICR is one of the world's leading cancer research institutes, aiming to defeat cancer. As a Senior Laboratory Technician you will contribute directly to this mission by supporting vital in vivo research. We are looking for a highly motivated, detail-oriented individual, committed to high-quality work. Key requirements include: Education and Knowledge BSc in Life Sciences or IAT Level 3 (Essential) Home Office Personal Licence (PILA, B, C) or equivalent (Essential) Understanding of tumour biology and pre-clinical models (Desirable) Skills Skilled in dissection, surgery, dosing of agents and sampling techniques (Essential) Strong organisational, communication and interpersonal skills (Essential) Ability to work independently and in a team with other scientists and BSU staff (Essential) Computer proficiency and willingness to pursue professional development (Essential) Experience Proven experience in in vivo oncology and PDX models (Essential) Strong foundation in animal (rodent) husbandry and behaviour (Essential) Experience in stereotaxic surgery, imaging techniques and sample preparation (Desirable) What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension Department/Directorate Information We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Bishani Wickrama via email on: [email protected].

Business Development Manager

  • Sutton
  • Business & Innovation Office
  • £61,275 - £74,175
  • Permanent

About the Role We are seeking a Business Development Manager to join The Institute of Cancer Research’s (ICR’s) Business and Innovation Office and contribute to to support a portfolio of academics by protecting and commercialising their research, supporting them in securing translational funding and to highlight to them the benefits of working with industry. The successful candidate will play a key role in strategic project evaluation, stakeholder engagement, IP protection, commercial deal-making (collaborations and licensing), and translational funding support. Key Responsibilities Identify and assess commercially viable research Protect IP and manage confidentiality agreements Draft and negotiate licensing and collaboration contracts Support translational funding applications Drive spinout opportunity management About You We are looking for a proactive, detail-oriented team player. PhD, MBA or equivalent in a relevant field Experience in business development or technology transfer Direct experience of negotiating and closing deals with external partners Strong communication, negotiation, and organizational skills What We Offer • Supportive, collaborative environment • Career development opportunities • Competitive salary and pension Department/Directorate Information The Business and Innovation Office drives commercialisation and strategic partnerships to maximise patient benefit. For more details, please refer to the job pack. For an informal discussion regarding the role, please contact Dr. Amritha Nair via Email on [email protected]

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

10/10/25

Suffering from psychological stress could further increase cancer risk in those already genetically predisposed to the disease, according to new research.

The findings show that the stress hormone cortisol increases the risk of breast and prostate cancer in people with BRCA mutations.

The research offers biological evidence that this high-risk group of patients could benefit from psychological interventions such as therapy and mindfulness to prevent the development of cancer.

The findings, from The University of Brighton and The Institute of Cancer Research, London, also indicate that targeting the cortisol receptor with a drug could be a potential strategy to help prevent cancer in those most at risk. Such drugs already exist and are approved for other conditions.

Inherited genes raise the risk of cancer

Mutations in the BRCA1 and BRCA2 genes – the latter of which was discovered at The Institute of Cancer Research (ICR) – are found in one in 400 people. They raise the risk of certain cancers, including breast and prostate, as cells are unable to repair DNA damage. Cortisol has previously been shown in the laboratory to damage DNA.

Through lab experiments on BRCA-mutated cells and long-term studies on people with BRCA mutations, the new research shows how stress impacts cancer development in this group.

Stress hormone cortisol affects DNA damage repair

The team found that BRCA-mutated breast cells treated with cortisol undergo DNA damage which is unable to be repaired – compared with non-BRCA cells, which were able to repair the DNA after 30 minutes.

The team also studied people with BRCA mutations and found that those who developed breast and prostate cancer had higher cortisol levels than those who did not.

Cortisol levels are higher in those who develop cancer

In research funded by the ICR – which is a charity as well as a research institute – Cancer Research UK, and the Rosetrees Trust, published in the British Journal of Cancer, the team looked at 62 female BRCA carriers who had been followed over 10 years.

They looked at levels of cortisol in plasma and urine samples taken over the years. Women with higher plasma cortisol levels were more than twice as likely to develop breast cancer than those with lower levels.

The team saw the same trend in 70 male BRCA carriers – the men who developed prostate cancer had higher cortisol levels. In these men, a marker of DNA damage was also higher in those who went on to develop prostate cancer.

The researchers say the results provide an insight into the mechanism by which stress may influence cancer, and that they highlight the potential of targeting the cortisol receptor to protect BRCA carriers from disease.

Prevention strategies should include psychological support

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London said:

“Certain genetic changes can significantly increase a person's risk of developing cancer, such as mutations in the BRCA genes – one of which was discovered here at the ICR. With this knowledge, we can take proactive steps to reduce that risk, such as preventative surgeries and regular screening to detect cancer early.

"Our study adds a new layer to this understanding by exploring how psychological stress interacts with these genetic mutations. We found that, in individuals with a BRCA mutation, stress may contribute to cancer development. This appears to be linked to cortisol, a stress hormone that can damage DNA – particularly in cells already compromised in their ability to repair themselves.

"Living with a BRCA mutation can be inherently stressful, and while these findings may seem concerning, they also empower us. Knowledge is power. By integrating psychological support – such as group therapy, mindfulness, and cognitive behavioural therapy – into prevention strategies, we can better protect those at risk. We hope that this will also drive research into future treatments targeting the cortisol receptor, to help prevent disease.”

Professor Melanie Flint, Professor of Stress and Cancer Research at the University of Brighton, said:

“Our data suggests that stress may play a role in cancer initiation in high-risk individuals however, further work is warranted to assess daily salivary cortisol levels to confirm this.”

‘Take steps to try to reduce stress levels’

Catherine Priestley, Senior Clinical Nurse Specialist at Breast Cancer Now said:

“When someone is diagnosed with breast cancer, it’s completely natural for them to wonder what has caused it. It’s important to remember that breast cancer risk is influenced by many different things – including genetics, lifestyle and environment, many of which are out of our control.

“This study suggests that high levels of the stress hormone cortisol could be contributing to breast cancer development in people who are already at high risk due to inherited altered BRCA genes. But it doesn’t mean that stress causes breast cancer. Stress and stressful life events happen to all of us. And while it wasn’t specifically looking at this group of people, we know from our landmark Breast Cancer Now Generations Study that stressful major life events like bereavement or divorce are unlikely to cause breast cancer.'

“But people experience stress very differently and we welcome more research like this to further understand the impact that stress can have on people’s physical health, wellbeing and quality of life.

“And we would always encourage people to take steps to try and reduce stress levels and look after their wellbeing in ways that are right for them, as well as reaching out for support if they need it.

“Anyone seeking information and support can speak to Breast Cancer Now’s expert nurses by calling the charity’s free, confidential helpline on 0808 800 6000 or on email, or visit breastcancernow.org.”